Rankings
▼
Calendar
CTMX Q4 2024 Earnings — CytomX Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
CTMX
CytomX Therapeutics, Inc.
$846M
Q4 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$38M
+43.2% YoY
Gross Profit
$38M
100.0% margin
Operating Income
$18M
46.4% margin
Net Income
$19M
49.6% margin
EPS (Diluted)
$0.24
QoQ Revenue Growth
+13.9%
Cash Flow
Operating Cash Flow
-$20M
Free Cash Flow
-$20M
Stock-Based Comp.
$2M
Balance Sheet
Total Assets
$121M
Total Liabilities
$121M
Stockholders' Equity
-$456,000
Cash & Equivalents
$38M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$38M
$27M
+43.2%
Gross Profit
$38M
$27M
+43.2%
Operating Income
$18M
-$606,000
+3017.3%
Net Income
$19M
$837,000
+2155.2%
← FY 2024
All Quarters
Q1 2025 →